Local Infiltration Analgesia in Bilateral Knee Arthroplasty - Efficacy of Subcutaneous Wound Infiltration With Local Anesthetic
This study has been completed.
Sponsor:
Hvidovre University Hospital
Collaborator:
Lundbeck Foundation
Information provided by:
Hvidovre University Hospital
ClinicalTrials.gov Identifier:
NCT00927225
First received: June 23, 2009
Last updated: NA
Last verified: June 2009
History: No changes posted
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Local infiltration analgesia is effective in total knee arthroplasty for postoperative pain management, but the efficacy of subcutaneous wound infiltration has not been evaluated. This study aims at evaluating the efficacy of subcutaneous wound infiltration in total knee arthroplasty in 16 patients undergoing bilateral knee arthroplasty.
| Condition | Intervention | Phase |
|---|---|---|
|
Pain, Postoperative |
Drug: ropivacaine 0.2%, 50 mL Drug: normal saline |
Phase 4 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Crossover Assignment Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor) Primary Purpose: Treatment |
| Official Title: | Local Infiltration Analgesia in Bilateral Knee Arthroplasty - Efficacy of Subcutaneous Wound Infiltration With Local Anesthetic. |
Resource links provided by NLM:
MedlinePlus related topics:
Knee Replacement
Drug Information available for:
Ropivacaine monohydrochloride
U.S. FDA Resources
Further study details as provided by Hvidovre University Hospital:
Primary Outcome Measures:
- Postoperative pain [ Time Frame: 1-6 hours postoperative ] [ Designated as safety issue: No ]
| Enrollment: | 16 |
| Study Start Date: | September 2008 |
| Study Completion Date: | June 2009 |
| Primary Completion Date: | June 2009 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Active Comparator: active
subcutaneous wound infiltration with 50 mL ropivacaine 0.2%
|
Drug: ropivacaine 0.2%, 50 mL |
|
Placebo Comparator: placebo
subcutaneous wound infiltration with 50 mL saline
|
Drug: normal saline |
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- total bilateral knee arthroplasty
Exclusion Criteria:
- immunological diseases
- treatment with opioids or steroids
- allergy to any drugs administered
Contacts and Locations
More Information
No publications provided by Hvidovre University Hospital
Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
| Responsible Party: | Lasse Andersen, Hvidovre Hospital |
| ClinicalTrials.gov Identifier: | NCT00927225 History of Changes |
| Other Study ID Numbers: | H-D-2008-104 |
| Study First Received: | June 23, 2009 |
| Last Updated: | June 23, 2009 |
| Health Authority: | Denmark: The Regional Committee on Biomedical Research Ethics |
Additional relevant MeSH terms:
|
Pain, Postoperative Postoperative Complications Pathologic Processes Pain Signs and Symptoms Anesthetics, Local Ropivacaine Anesthetics |
Central Nervous System Depressants Physiological Effects of Drugs Pharmacologic Actions Sensory System Agents Peripheral Nervous System Agents Central Nervous System Agents Therapeutic Uses |
ClinicalTrials.gov processed this record on May 19, 2013